[Prognostic factors of infiltrating tumors of the bladder].
In France, invasive bladder cancer is the more frequent urologic malignancy after prostate carcinoma. Treatment of bladder cancer is radical cystectomy. New therapeutic approaches such as chemoradiation combination for a conservative procedure, neoadjuvant or adjuvant chemotherapy are still developing. In this way, a rigorous selection of patients is needed. This selection is based on prognostic criteria that could be divided into four groups: i) the volume of the tumor including the tumor infiltration depth, the nodal status, the presence or not of hydronephrosis and the residual tumor mass after transuretral resection; ii) the histologic aspects of the tumor including histologic grading, the presence or not of an epidermoid metaplasia, of in situ carcinoma or of thrombi; iii) the expression of tumor markers (tissue polypeptide antigen, bladder tumor antigen); iv) the biologic aspects of the tumor as ploidy, cytogenetic abnormalities, expression of Ki67, expression of oncogenes or tumor suppressor genes, expression of tumor antigens or growth factor receptors. This paper reviews the prognostic value of the various parameters.
Maulard-Durdux
C
C
Service d'oncologie-radiothérapie, hôpital Tenon, Paris, France.
Housset
M
M
D014408:Biomarkers, Tumor / Q000097:blood / Q000652:urine; D002453:Cell Cycle; D002869:Chromosome Aberrations; D015870:Gene Expression; D016147:Genes, Tumor Suppressor; D017405:Herpes Simplex Virus Protein Vmw65 / Q000032:analysis; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000652:urine / Q000821:virology
D014408:Biomarkers, Tumor; D017405:Herpes Simplex Virus Protein Vmw65